

MDS and AA Expert Forum
Sunday 17 September 2017
with live video broadcasting



Objectives

- Highlight progress in understanding the pathogenesis and diagnosis of MDS and AA
- Revisit emerging efforts to optimize comprehensive care in the management of MDS and AA including guideline updates
- Illustrate the optimal use of iron chelation therapy for MDS and AA patients in clinical practice
- Discuss the role of thrombopoietin receptor agonists in the management of patients with severe AA

Time in Taipei	Topic	Speaker/Chair	Site
14:00-14:10	Welcome and introduction	Boris Afanasyev Ming-Chih Chang	St Petersburg Taipei
14:10-14:30	Progress in understanding the pathogenesis of MDS	Heather Leitch	Taipei
14:30-14:45	MDS ClearPath: Introduction to the algorithm for the management of MDS in Canada	Heather Leitch	Taipei
14:45-15:05	Management of MDS and guideline updates	Aristoteles Giagounidis	St Petersburg
15:05-15:25	What do we know about the pathogenesis of AA today?	Philip Scheinberg	St Petersburg
15:25-15:45	Contemporary management of AA and recent advances	Philip Scheinberg	St Petersburg
15:45-16:05	Q&A	All	
16:05-16:25	Coffee break		
16:25-16:45	Iron chelation in clinical practice: The MDS and AA perspective	Heather Leitch	Taipei
16:45-17:05	Thrombopoietin receptor agonist in severe AA: From evidence to practice	Philip Scheinberg	St Petersburg
17:05-17:20	Q&A	All	
17:20-17:50	Panel discussion Bone marrow transplant for MDS and AA: Risks and outcomes Chairs: Aristoteles Giagounidis, Heather Leitch Panel: Philip Scheinberg, local BMT experts • Presentation by a BMT expert from Taiwan (5-7 mins) • Presentation by a BMT expert from Russia (5-7 mins) • Discussion (16-20 mins)	Bor-Shen Ko Ming-Chih Chang	Taipei
		TBC	St Petersburg
		Boris Afanasyev Ming-Chih Chang	St Petersburg Taipei
17:50-18:00	Meeting summary	Heather Leitch	
18:00-19:00	Taiwan local panel discussion Clinical management in MDS and AA	Ming-Chih Chang Bor-Shen Ko	Taipei

Novartis (Taiwan) Co., Ltd.
11th floor, No.99, Section 2
Jen-Ai Road
Taipei 10062
Taiwan

TW1707676069

 NOVARTIS